Abstract
JACEMIN is an autologous cultured epidermis maintaining melanocytes, approved for manufacture and sale in March 2023 and covered by insurance in October 2024 as a regenerative medical product. This product is produced by isolating and culturing epidermal cells, including melanocytes, from a patient’s own healthy skin tissue, forming a sheet structure. JACEMIN is transplanted into areas affected by vitiligo where nonsurgical therapy is ineffective or not indicated, after the epidermal layer has been removed（shaved thinly）. Through this transplantation, the patient’s own melanocytes are supplied along with epidermal cells, leading to repigmentation.
